433 related articles for article (PubMed ID: 24599767)
1. Severe cutaneous adverse reactions related to systemic antibiotics.
Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
[TBL] [Abstract][Full Text] [Related]
2. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature.
van Hattem S; Beerthuizen GI; Kardaun SH
Br J Dermatol; 2014 Dec; 171(6):1539-45. PubMed ID: 24888401
[TBL] [Abstract][Full Text] [Related]
3. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
[TBL] [Abstract][Full Text] [Related]
4. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
5. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention.
Zhang C; Van DN; Hieu C; Craig T
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):483-487. PubMed ID: 31400461
[TBL] [Abstract][Full Text] [Related]
7. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
8. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia].
Gamba C; Schroeder J; Citterio A; Cazzaniga S; Rivolta AL; Vighi G;
Recenti Prog Med; 2014 Oct; 105(10):379-84. PubMed ID: 25282350
[TBL] [Abstract][Full Text] [Related]
9. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
[TBL] [Abstract][Full Text] [Related]
10. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
[TBL] [Abstract][Full Text] [Related]
11. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
12. Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore.
Lee HY; Chou D; Pang SM; Thirumoorthy T
Int J Dermatol; 2010 May; 49(5):507-12. PubMed ID: 20534083
[TBL] [Abstract][Full Text] [Related]
13. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of cutaneous adverse drug reactions.
Mockenhaupt M
Chem Immunol Allergy; 2012; 97():1-17. PubMed ID: 22613850
[TBL] [Abstract][Full Text] [Related]
15. Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study.
Su P; Aw CW
Int J Dermatol; 2014 Nov; 53(11):1339-45. PubMed ID: 25070588
[TBL] [Abstract][Full Text] [Related]
16. Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results.
Huang PW; Chiou MH; Chien MY; Chen WW; Chu CY
J Formos Med Assoc; 2022 Aug; 121(8):1397-1405. PubMed ID: 34674904
[TBL] [Abstract][Full Text] [Related]
17. Adverse cutaneous drug eruptions: current understanding.
Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
[TBL] [Abstract][Full Text] [Related]
18. Adverse cutaneous drug reactions in a single quaternary referral hospital.
Botelho LF; Porro AM; Enokihara MM; Tomimori J
Int J Dermatol; 2016 Apr; 55(4):e198-203. PubMed ID: 26710962
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]